ArticleAJNR. American journal of neuroradiology2026
Precision Diffusion-Weighted Imaging of Head and Neck Squamous Cell Carcinoma.
Article in AJNR. American journal of neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multiparametric MRI Assessment of Cervical Lymphadenopathy: Combined Diagnostic Performance of Morphological Features and Apparent Diffusion Coefficient.Healthcare (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
background and purposeHead and neck squamous cell carcinoma (HNSCC) represents a serious global health burden, with over 890,000 new cases annually and approximately 450,000 related deaths worldwide. Our study aims to optimize DWI sequences for the head and neck and determine reproducibility metrics values for ADC, allowing clinicians to distinguish between genuine physiologic changes and measurement errors. MATERIALS AND
methodsWe optimized the head and neck DWI protocol using Qualitative Initiative Biomarker Alliance (QIBA)-recommended parameters, high 2000 b-value, Zoom-IT technology, and a polyvinylpyrrolidone phantom calibration. Twenty-six biopsy-proved patients with HNSCC underwent pretreatment "coffee-break" test-retest DWI scans on a Siemens 3T Vida MRI scanner. ADC values were extracted from 46/51 segmented tumor regions (either tumor mass or metastatic lymphadenopathy), and reproducibility measures were assessed using the within-subject coefficient of variation (wCV), repeatability coefficient, and intraclass correlation coefficient (ICC). Bland-Altman plots and correlation analyses were used to evaluate measurement precision. Both manual segmentation by 2 expert neuroradiologists and semiautomated methods of segmentation were utilized.
resultsOut of 51 identified tumor masses, 46 were included in the final analysis. The Bland-Altman plot revealed minimal bias in ADC values between test-retest scans. The calculated 5.2-5.4% wCV resulted in a repeatability coefficient of 14.4%. The ICC between test and retest measurements was 0.8-0.83, indicating good test-retest reliability. The Dice score between the 2 expert readers for all parameters indicated excellent agreement between segmentations performed by different readers, with values of 0.991 for the test measurement and 0.976 for the retest measurement.
conclusionsOur findings support the use of an optimized DWI protocol for accurate and reproducible ADC quantification in HNSCC, which is comparable with or better than the percent repeatability coefficient derived from QIBA profiles for breast, liver, and prostate, though it is inferior to those for the brain. Further quantitative imaging biomarker Stage 2-type profile research is necessary to refine imaging parameters, improve reproducibility markers, and establish DWI as a clinical standard for evaluating HNSCC tumor recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.